ARTAN Bio raises $200K seed from VitaDAO to advance longevity tRNA platform
What's the deal? ARTAN BioDealroom has a profile for this one. Try Dealroom →, a longevity biotech startup based in St. Petersburg, Florida, has closed a $200,000 seed raise to advance its engineered suppressor tRNA platform — a technology designed to correct genetic errors linked to ageing and age-related diseases. The funding came through VitaDAODealroom has a profile for this one. Try Dealroom →, a decentralised autonomous organisation that funds longevity research via community governance and IP-NFTs.
The money will go toward animal model validation, development of a preclinical candidate, and intellectual property filings. ARTAN Bio has already completed initial in-cell validation of its core technology, called ARTAN-102, through an earlier seed raise with VitaDAO.
Why now? The raise coincides with ARTAN Bio chief executive Anthony Schwartz's presentation at the NFC Summit in Lisbon on June 4, where he will discuss the company's platform and its decentralised science (DeSci) model. The startup operates out of spARK LabsDealroom has a profile for this one. Try Dealroom → by ARK InvestDealroom has a profile for this one. Try Dealroom →, placing it within a growing ecosystem of longevity-focused ventures.
ARTAN Bio's technology targets nonsense mutations — genetic errors that cause proteins to stop being made prematurely. These mutations are implicated in a wide range of ageing-related and genetic diseases, making them a potentially broad therapeutic target.
What could go wrong? At $200,000, this is a modest raise for a biotech company moving into animal studies and IP protection. Preclinical development is expensive, and ARTAN Bio will likely need significantly more capital to reach meaningful milestones.
The decentralised funding model itself carries risks. Governance token holders ($VITARNA) participate in decisions on research priorities and IP licensing — a structure that could complicate decision-making as the science grows more complex. The press release explicitly notes that VITARNA tokens are not securities, a disclaimer that signals regulatory ambiguity around such instruments.
The signal: VitaDAO, classified as a corporate investor on Dealroom, continues to carve out a distinctive niche by funding early-stage longevity research that sits well below the ticket sizes traditional biotech VCs would consider. ARTAN Bio's $200,000 raise underscores how decentralised science models are filling a genuine gap at the pre-seed and seed level, where promising but unproven platforms struggle to attract conventional capital. Whether DeSci mechanisms can support the significantly larger rounds needed for clinical development remains the critical test for both ARTAN Bio and the model itself.
Read more: prnewswire.com
